High Level Darunavir Resistance in a Patient with HIV-1 RNA Rebound Under Antiretroviral Treatment

Müge TOYGAR DENİZ¹, Murat SAYAN²,³, Sıla AKHAN¹

Abstract

Today, antiretroviral therapies are successful in chronic HIV infection and have improved survival outcome. However antiretroviral drug resistance, coinfection, comorbidity and management of drug interactions are prominent in long-term treatments. In this study, we aimed to present the management of antiretroviral treatment in the light of high levels of darunavir resistance in a patient who is incompatible with antiretroviral therapies. HIV-1 drug resistance analysis was frequently applied because our patient was not compatible with the treatment. Minimally interacting agents with antiretroviral therapy could be selected in developing pulmonary tuberculosis. In addition, in the developing acute renal failure, genetic barrier anxiety could be left behind. Our findings suggest that HIV-1 drug resistance analysis should be an integral part of the management of antiretroviral treatment in developing co-infections and comorbidities in an incompatible patient.

Keywords: HIV, darunavir, protease inhibitors, drug resistance

Introduction

Chronic HIV infection continues to increase worldwide. According to the latest information from the Joint United Nations Program on HIV / AIDS (UNAIDS), 37.9 million people worldwide live with HIV (1). Although there is a relative increase of 20% in the total number of patients compared to 2010, the number of new HIV infections diagnosed as of the end of 2018 is 1.7 million and this

¹ Kocaeli University Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Kocaeli, Turkey
Phone number: +90 506 585 65 24 - +90 262 303 70 84
e-mail: mugedeniz90@gmail.com
² Kocaeli University, Faculty of Medicine, Clinical Laboratory, PCR Unit, Kocaeli, Turkey
³ Near East University, DESAM Institute, Nicosia, Northern Cyprus
DOI: 10.17932/EJOH.2020.022/ejoh_v01i1007
High Level Darunavir Resistance in a Patient with HIV-1 RNA Rebound Under Antiretroviral Treatment

number has decreased by 16% compared to 2010. Similarly, by the end of 2018, the annual rate of HIV-related deaths has been reduced by 33% compared to 2010. This relative improvement in the HIV infection dynamics appears to have been achieved by increased access to antiretroviral therapy. According to the World Health Organization (WHO) data, today 23.3 million people living with HIV have access to antiretroviral treatment. According to estimation analysis, it is targeted to reach 33 million people by 2030 (2). On the other hand, in Turkey, there are 24,237 HIV-infected individuals confirmed as of July 2020 and approximately five people are infected with HIV-1 every day (3). According to other source, the International Pharmaceutical Market Database’s (IMS) current data for Turkey (October 2019) 16,806 of our patients have access to antiretroviral treatment and 338 cases of the patients are under treatment with darunavir (11).

A combination treatment of two nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitor (INI) or enhanced protease inhibitor (PI) drug groups is recommended for an HIV-infected individual who has not previously received antiretroviral therapy (9). This combination treatment regimen is called combined antiretroviral therapy (cART), and studies have shown that HIV replication is suppressed and CD4 + T lymphocyte cell count increases when this form of treatment is started (7,8).

In Turkey, the primary antiretroviral resistance ratio was determined to be 7.6% in patients infected with HIV. The distribution of resistance by drug groups is 4.2% in the NRTI group, 1.7% in the NNRTI group, and 1.7% in the PI group (12). However, a significant part of drug resistance emerges as acquired resistance due to inappropriate drug use.

Darunavir (DRV), a non-peptidic protease inhibitor, is effective on HIV protease by inhibiting enzymatic dimerization. DRV is an agent that is effective against PI resistant HIV strains both in vitro and in vivo, has a high genetic barrier, and resistance development is rare (5). In order to determine that the level of resistance to darunavir is high, at least four mutations must be present among the major mutations in the gene region encoding HIV protease (I50V / L, I54A / L / M / S / T / V, L76V, V82A / C / F / L / M / S / T, I84A / C / V, N88D/G/S/T, L90M in, N88D / G / S / T, L90M) (4).

This study aims to present the management of a case with a high level darunavir resistance seen in our country for the first time.
Case Report

A twenty-five-year-old male patient was admitted to our hospital in 2009 after receiving positive results from the HIV antibody test before being operated on due to spontaneous pneumothorax. In routine tests, the patient’s hemogram and biochemistry values were normal, CMV IgM negative, CMV IgG positive, toxoplasma IgM and IgG negative, anti-HCV, HBs Ag, anti-HBs, anti-HBc IgG negative, and anti HAV IgG positive serology result. Lymphocyte cell count was 98 cells / mm³, HIV-1 RNA load was 1,260,000 IU / ml. Antiretroviral drug resistance test before treatment showed the patient was sensitive to all drug groups. The patient was started on tenofovir / emtricitabine (TDF + FTC) + lopinavir / ritonavir (LPV / r) therapy and prophylaxis treatment for opportunistic infections.

Because the patient took medication irregularly, HIV-1 RNA did not become negative in May 2011, no resistance was detected to the NNRTI, NRTI and PI group drugs. HIV-1 drug resistance analysis was done by the Sanger dideoxy sequencing method. In the HIV-1 pol gene, the protease region (codon 1 to 99) and reverse transcriptase site (codon 1 to 235) were sequenced. In the resulting nucleotide sequences, mutations were identified in the Stanford HIVdb v8.7 program and clinical significance analyses were performed according to the World Health Organization-Transmitted Drug Resistance Mutation (WHO-TDRM) list (6). The treatments and drug resistance analyses performed since the beginning of patient follow-up are shown in Table 1. In addition, the patient’s HIV-1 RNA load and CD4⁺ T lymphocyte cell count dynamics in the time series are shown in Figure 1.

In January 2018, antituberculosis treatment was initiated on the patient with positive asido-resistance bacilli (ARB) analysis in the sputum and compatible lung tomography. Antiretroviral therapy was administered as TDF / FTC + efavirenz (EFV) due to drug interaction. Because of a high resistance barrier and minimal drug interaction, the patient’s treatment was arranged as TDF / FTC + dolutegravir (DTG) in May 2018. The patient’s irregular drug use was ongoing at this time. In the control analyzes requested in the first month of this treatment, the number of CD4⁺ T lymphocyte cells was 33 cells / mm³, the HIV-1 RNA load was 3.440.000 IU / ml, and the concurrent resistance analysis showed sensitivity to zidovudine (ZDV), EFV, DRV agents and INI drug. The new treatment was arranged as DRV / r + EFV due to sensitivity to the group.

In the HIV-1 drug resistance analysis done in November 2018, in the NRTI drug class, D67G, K70E gene mutations; in the NNRTI drug class, L100I, K103N gene mutations; in the PI drug class, V32I, M46I, I47V, V82A, I84V gene mutations;
and in INI drug class, L33F, K43T, F53L gene mutations were detected. Upon
determination of these mutations, it was determined that the NNRTI group was
highly resistant, the PI group was highly resistant, and the NRTI group was
considered to be abacavir, stavudine, didanosine-moderately resistant, tenofovir
low-level, and ZDV sensitive. This is why the new treatment was arranged as
ZDV + TDF / FTC + DTG.

In February 2019, as a result of abdominal tomography taken due to prolonged
diarrhea, abdominal pain, vomiting and inability to urinate, a fistula extending
from the anorectal junction to the bladder and right renal abscess as well as grade
2 hydronephrosis was detected. Operation was not considered by general surgery
clinics and a bilateral nephrostomy was opened in the patient for postrenal acute
renal failure. Treatment with meropenem and tigecycline antibiotherapy and
antiretroviral therapy was changed to ZDV + tenofovir alafenamide / emtricitabine
/ cobicistat / elvitegravir (TAF / FTC / EVG / c) due to the high creatinine value
(2.67 mg / dl). Under this treatment, the control HIV-1 RNA load was negative in
August 2019, and the number of CD4 + T lymphocyte cells was determined as 60
cells / mm3. However, the general condition of the patient worsened and exitus
was accepted due to intra-abdominal sepsis.

Discussion

DRV, which is an agent that is difficult to develop resistance to due to
incompatibility in our case, was chosen, but during the 5th month of treatment,
a high level of darunavir resistance was encountered. Disruption of a potent
antiretroviral agent makes treatment management more difficult, although the
treatment options are much more common today. On the other hand, with DTG,
another agent with high genetic barrier, resistance mutations developed against
the drug groups that the patient has previously used irregularly are suppressed.
It should be remembered that HIV mutations are archived and can be detected
in the plasma again as a result of drug group changes, even if they are sensitive
to drug resistance analysis. In our case, the K103N mutation associated with
EFV resistance was able to reappear long after treatment. On the other hand,
the M184V mutation associated with the NRTI class is blamed for resistance
to emtricitabine. However, despite the presence of a M184V mutation, when a
potent antiretroviral is added from another drug class, M184V may not cause a
problem (10). This detail can be valuable if there are limited options in patient
management.

Increased viral load of our patient after one month of TDF / FTC + DTG caused
drug changes to be made despite the high genetic barrier of DTG. However, the
reason why the resistance test result turns out to be EFV sensitive is most likely
because the high genetic barrier dolutegravir suppresses mutated strains in the plasma. Drug changes should be made by experts by evaluating the patient’s previous drug history and resistance history together.

In the follow-up of our case as a result of being incompatible with treatment, HIV-1 drug resistance analysis was frequently used. In developing pulmonary tuberculosis, minimally interacting EFV and DTG agents could be selected with antiretroviral therapy, as well as genetic barrier anxiety could be left behind in developing acute renal failure. Our findings show that HIV-1 drug resistance analysis should be an integral part of antiretroviral therapy management in patients’ co-infections and comorbidity.

Conflict of Interest

The authors did not report any conflicts of interest.

References


